Shenogen, Lee's forge another cancer combo deal

Lee's Pharmaceutical Holdings Ltd. (HKSE:0950) and Shenogen Pharma Group Ltd. (Beijing, China) partnered to jointly develop and commercialize a combination therapy in China to treat late-stage cancers. The therapy will comprise ZKAB001, which is a mAb against PD-L1 from Lee's, and Shenogen's icaritin (SNG-162), a small molecule derived from a Chinese herb targeting estrogen receptor alpha 36.

The partners expect synergistic effects from the combo based on animal studies. ...